Jenburkt Pharmaceuticals Ltd — Results, 20-05-2025: Result

Jenburkt Pharmaceuticals Limited has announced a board meeting to approve the financial results for the quarter and financial year. The Board approved the standalone audited financial results for FY 2024-25, declaring a 180% dividend per equity share. The 40th Annual General Meeting will be held via video conferencing. Shri Ashish Uttam Bhuta has been appointed as a director on rotation and re-appointed as Chairman and Managing Director for five years from April 2026, with approved remuneration terms for three years. The auditors issued an unmodified opinion on the standalone audited results. The company reported revenue growth with profit after tax at Rs. 3206.06 Lacs for FY 2024-25 against Rs. 2597.73 Lacs last year. Internal controls and audit systems were found adequate and effective, with no material irregularities noted.